Incorporating Real-World Data into Named Patient Programmes Generating compliant, decision-useful evidence during early access in India without regulatory reclassification FORM 12B GUIDANCE INDIA CDSCO
Strategic Objective The Challenge How can we capture meaningful real-world evidence during Named Patient Import programmes whilst maintaining full regulatory compliance? The Solution A properly structured RWD overlay that preserves the non- interventional nature of Form 12B access programmes, ensuring CDSCO alignment whilst building valuable clinical insights for internal learning and future regulatory strategy.
Regulatory Guardrails
Non-Negotiable Boundaries Non-Interventional Status Named Patient Import under Form 12B must remain strictly observational with no protocol- driven treatment assignment or hypothesis testing No Mandated Schedules Follow-ups cannot exceed standard of care. No mandatory visit protocols or study-driven assessments are permitted Evidence Positioning RWD cannot be positioned as pivotal clinical evidence for registration. Data collection must be observational, voluntary, and retrospective
Permissible RWD Scope
What You Can and Cannot Collect Allowed (Compliant) Patient demographics (age, sex) Diagnosis and indication details Prior lines of therapy history Dosing patterns and treatment duration Safety outcomes (AEs, SAEs) Physician-assessed clinical response Survival status and discontinuation reasons Not Allowed (Red Flags) Randomisation No control arms or comparative study design elements Mandatory Visits No protocol-driven schedules beyond standard care Efficacy Claims No comparative effectiveness positioning or promotional messaging Protocol Endpoints No pre-specified primary or secondary outcomes as in clinical trials Study Language Informed consent cannot reference "study", "trial", or "research"
Three-Layer Structural Model
The RWD Overlay Approach Observational RWD Registry Optional, physician-led, voluntary, de-identified Pharmacovigilance Mandatory ADR reporting and SAE timelines Named Patient Import Form 12B, prescription-based access only Critical Principle: Access does not equal data collection. Data collection is independent, optional, and strictly separated from the access programme to maintain regulatory compliance.
Operational Design
How to Collect RWD Compliantly 01 Physician Engagement Independent clinical judgement preserved with voluntary data-sharing agreements. No financial incentives linked to data provision or collection activities 02 Patient Consent Separate data privacy consent obtained, compliant with Indian DPDP Act. Documentation must avoid any reference to clinical research or study participation 03 Data Capture Tools Simple physician eCRF limited to 5310 essential fields. Retrospective entry only with no mandated timelines or follow-up schedules imposed
Governance and Compliance Controls Ethics Oversight Independent observational declaration filed with appropriate institutional review Pharmacovigilance Integration Seamless SAE reporting pathways aligned with PSMF requirements Data Protection De-identified datasets with aggregate analysis only, ensuring patient privacy Promotional Safeguards Strict prohibition on outcome claims or comparative effectiveness messaging Regulatory Firewall Clear internal separation between access, PV, and RWD collection functions
Strategic Value
How RWD Can Be Used Safely Permitted Uses Safety Signal Strengthening Enhanced understanding of adverse event profiles in real-world Indian patient populations Treatment Pathway Mapping Insights into prescribing patterns, prior therapies, and clinical decision-making context Regulatory Strategy Internal learning to inform labelling strategy, post-marketing commitments, and future trial design Health Economics Real-world inputs for health technology assessments and reimbursement discussions Prohibited Uses Trial Replacement Cannot substitute for required Indian clinical trials in registration dossiers Promotional Claims No efficacy or comparative effectiveness messaging in commercial communications Pivotal Evidence Cannot be positioned as primary evidence in regulatory submissions to CDSCO
Risk Management Framework Programme Seen as Clinical Trial Mitigation
Keep RWD voluntary and retrospective with clear separation from access provision Regulatory Reclassification Mitigation: Separate consent documentation and maintain non-interventional structure throughout Promotional Violation Mitigation: Strict prohibition on outcome claims, comparisons, or effectiveness messaging Data Misuse or Breach Mitigation: Robust governance frameworks with compliance oversight and regular audits
Executive Recommendation Strategic Approach Implement Named Patient Programme with RWD Overlay using strict functional separation and governance controls CEO Decision Framework
- Access and Revenue Use Form 12B for patient access and early revenue generation in Indian market
- Learning and Confidence Use RWD overlay for internal learning, safety insights, and regulatory strategy refinement
- Registration Integrity Preserve full CDSCO registration pathway integrity without compromising future approval prospects